Orally disintegrating films, or ODFs, are thin sheets that melt rapidly against the oral mucosa, releasing their payload for absorption without the need to swallow. Conventional ODFs rely almost exclusively on hydrophilic polysaccharides such as pullulan, hydroxypropyl methylcellulose, and pregelatinized starch, which disintegrate quickly; published examples include hydroxypropyl cellulose films that vanish in water in about 12.5 seconds and hydroxypropyl methylcellulose formulations that break down in roughly 43 seconds. But these matrices carry little nutritional value, and protein hydrolysate alternatives are prohibitively expensive. Soy protein isolate, a widely available and inexpensive plant protein with excellent film-forming ability and a rich amino acid profile, seemed like an obvious candidate, except that its dense, flexible molecular packing causes films to disintegrate sluggishly in water, sometimes lagging far behind their polysaccharide competitors.

The team’s answer was β-cyclodextrin, a cyclic oligosaccharide with a hydrophobic interior cavity and a hydrophilic, hydroxyl-covered exterior. Cyclodextrins are workhorses in food and pharmaceutical science, used to emulsify, solubilize, mask unpleasant flavors, and protect sensitive bioactive compounds. Previous work by some of the same authors had shown that β-cyclodextrin could accelerate the disintegration of soy protein films by disrupting the tight packing of protein chains. The new study asked whether the molecule could do double duty: remodel the protein network for rapid release while also protecting ergothioneine, a sulfur-containing antioxidant first isolated in 1909 from the fungus Claviceps purpurea and produced by edible fungi and cyanobacteria.

Ergothioneine was a demanding guest. Its unusually low redox potential of −60 millivolts makes it resistant to autoxidation, and studies have shown it outperforms glutathione at scavenging hydroxyl radicals, peroxyl radicals, and singlet oxygen. Yet antioxidant activity in ergothioneine-containing systems is known to decline during thermal processing and storage, likely through oxidative degradation. The researchers cast films by dissolving 2.0 grams of soy protein isolate in water at 75 degrees Celsius, adding 10 milligrams of ergothioneine, 0.7 grams of D-sorbitol as a plasticizer, and β-cyclodextrin at 0, 5, 10, and 15 percent of the dry protein weight, then drying the solutions in Petri dishes at 40 degrees Celsius for eight hours.

Microscopy revealed how dramatically the additive reshaped the material. The pristine soy protein film was rough and inhomogeneous, riddled with micropores and aggregated particulate domains, while adding ergothioneine alone smoothed the surface, apparently by promoting the unfolding of protein polypeptide chains. The real transformation came at 10 percent β-cyclodextrin, where the films displayed an extremely smooth, dense, defect-free surface organized into a continuous reticular network. The authors attribute this to hydrogen bonding between the cyclodextrin’s abundant hydroxyl groups and the protein network, which suppresses pore formation during drying. At 15 percent, however, the strategy backfired: bright, angular crystalline aggregates appeared across the surface, evidence that excess cyclodextrin had exceeded its solubility limit and phase-separated into β-CD-rich crystalline domains, shattering the structural continuity of the protein matrix.

Those structural changes translated directly into performance. The water contact angle, a measure of surface wettability, fell from 63.77 degrees in the control film to 36.28 degrees at 10 percent cyclodextrin, reflecting a far more hydrophilic surface that welcomes water penetration. Tensile strength climbed from 10.37 megapascals in the control to 12.15 megapascals at the optimal loading, and elongation at break rose from 3.462 to 4.376 percent, meaning the films became both stronger and more flexible. Then came the headline result: in vitro disintegration time dropped from 31.67 seconds in the control to 15.46 seconds at 10 percent cyclodextrin, a 45 to 52 percent improvement across the cyclodextrin-containing formulations, comfortably meeting the sub-60-second benchmark for fast-disintegrating films. Intriguingly, the 15 percent formulation showed no significant further gain, because its added thickness lengthened the path water had to travel, canceling out its extra hydrophilicity.

The loading data told a similarly encouraging story. High-performance liquid chromatography showed that ergothioneine loading efficiency rose from 66.83 percent in films without cyclodextrin to 76.33 percent at the 10 percent level, with loading capacity peaking at 2.16 micrograms per milligram of film. Relative standard deviations across replicate films stayed below 4 percent, confirming that the solvent casting method produces reproducible, uniformly dosed films. Each standard 15-by-15-millimeter dosing unit carried about 16.21 micrograms of ergothioneine in the optimal formulation. Surface pH values for all films ranged from 5.55 to 6.48, safely within the range tolerated by oral tissue, and mucoadhesive forces were essentially unchanged at moderate additive levels, reaching 0.69 newtons only in the phase-separated 15 percent formulation, where crystalline protrusions increased contact area.

The protective half of the dual function emerged under stress. The team sealed films in ordinary plastic bags and stored them for 28 days at 40 degrees Celsius, 75 percent relative humidity, under continuous fluorescent light to simulate accelerated oxidative aging. Films containing ergothioneine alone watched their DPPH radical scavenging activity collapse from 83.47 percent on day zero to 40.86 percent by day 28, with ABTS activity falling in parallel from 85.21 to 41.74 percent. Films with 10 percent cyclodextrin retained 60.57 percent DPPH activity and 60.68 percent ABTS activity over the same period, significantly better than every other formulation. Spectroscopic characterization supported the mechanism: X-ray diffraction showed the amorphous protein film acquiring the characteristic crystalline peaks of β-cyclodextrin, while Fourier-transform infrared spectroscopy revealed strengthened hydrogen bonding bands at 3288, 1641, and 1537 reciprocal centimeters, along with new peaks marking the cyclodextrin skeleton. Thermogravimetric analysis showed the maximum decomposition temperature rising steadily with cyclodextrin loading, from 300.28 degrees Celsius in the control to a peak of 314.63 degrees, confirming a more thermally robust composite.

The authors are careful about how far the interpretation can go. Because the antioxidant assays measure total radical scavenging of the entire film matrix rather than residual ergothioneine concentration directly, and because no inclusion complex between cyclodextrin and ergothioneine was demonstrated, the improved retention may reflect reduced oxidative exposure through intermolecular interactions and a denser matrix rather than the specific stabilization of individual ergothioneine molecules. The disintegration tests also used distilled water rather than simulated saliva, and all evaluations were in vitro. Future work employing HPLC or LC-MS quantification of ergothioneine, phase-solubility analysis, differential scanning calorimetry, and two-dimensional NMR is needed to pin down the molecular fate of the antioxidant during storage.

Even with those caveats, the implications are considerable. The study breaks the disintegration barrier that has kept soy protein out of serious consideration for orally disintegrating films, and it does so with a cheap, food-grade cyclodextrin that simultaneously improves mechanical strength, thermal stability, and antioxidant retention. For the food and pharmaceutical industries, the platform suggests a practical route to delivering sensitive bioactive compounds, from ergothioneine to other oxidation-prone nutraceuticals, in a fast-dissolving, plant-protein-based format that adds nutritional value instead of diluting it. If longer-term storage studies and in vivo safety testing bear out the accelerated results, the humble soybean may find itself at the leading edge of oral thin-film technology, one 15-second melt on the tongue at a time.

Subject of Research: Development of soy protein isolate-based orally disintegrating films using β-cyclodextrin to enhance disintegration and protect ergothioneine

Article Title: Development of soy protein isolate-based orally disintegrating films: The dual role of β-Cyclodextrin in enhancing disintegration performance and ergothioneine stability

Article References: Zhou, Y., Du, X., Lv, C., Tian, Y., Guo, S., Guo, Z., & Wang, Z. (2026). Development of soy protein isolate-based orally disintegrating films: The dual role of β-Cyclodextrin in enhancing disintegration performance and ergothioneine stability. Food Chemistry: X, 39, Article 104451. https://doi.org/10.1016/j.fochx.2026.104451

Image Credits: AI Generated

DOI: 10.1016/j.fochx.2026.104451

Keywords: orally disintegrating films, soy protein isolate, β-cyclodextrin, ergothioneine, oral drug delivery, antioxidant stability, film disintegration, hydrogen bonding, plant protein, Food Chemistry: X, bioactive compound protection, solvent casting

The Gini coefficient takes a value between zero and one. In economics, a value of zero would mean everyone earns exactly the same income, while a value approaching one means a single individual holds nearly all the wealth. The researchers reasoned that the same logic applies to metabolite concentrations measured across a population of samples. If a molecule is homeostatically regulated by cells, tissues, or the organism as a whole, its concentration should be similar from person to person, yielding a low Gini coefficient. Conversely, a molecule that is exogenous, such as a pharmaceutical drug that only some individuals have ingested, should show wildly unequal concentrations across a cohort, producing a Gini coefficient close to one.

To test this idea, the team mined publicly available metabolomics datasets, including a large study of more than 200 identified plasma metabolites measured in 1,125 individuals with chronic obstructive pulmonary disease, available through the Metabolomics Workbench. The results were striking. Endogenous metabolites, which the authors call endogenites, peaked in their Gini distribution at around 0.2, while exogenous molecules such as drugs and food-derived compounds peaked above 0.95. The median Gini coefficient across the entire dataset was 0.263. When the researchers classified molecules by origin, 73 percent of exogenous molecules had Gini coefficients above 0.5, compared with just 2.9 percent of molecules considered endogenous or regulated.

Among the most tightly controlled molecules were the amino acids. Essential and non-essential amino acids had identical average Gini coefficients of just 0.14, and nine of the 25 lowest Gini values in the dataset belonged to amino acids including methionine, arginine, proline, serine, phenylalanine, asparagine, tryptophan, lysine, and glutamine. Glutamine itself recorded the lowest value of all, a Gini coefficient of 0.066 with a 95 percent confidence interval of just 0.063 to 0.068, a figure even lower than any observed in the team’s earlier transcriptomics analyses. Given that glutamine is a major hub of nitrogen metabolism, such extreme uniformity makes biological sense and suggests the molecule could even serve as a normalisation standard in metabolomics studies where sample volumes are uncertain.

At the opposite extreme sat pharmaceutical compounds. The anticonvulsant lamotrigine, for example, posted a Gini coefficient of 0.99, meaning its presence in plasma was almost entirely confined to the small subset of participants taking the drug. In a second dataset of 681 serum metabolites from 340 individuals studied in the context of tuberculosis, the highest values belonged to metabolites of paracetamol and aspirin. The researchers also examined vitamins, which occupy an interesting middle ground: they are essential and therefore physiologically important, yet exogenous in origin. Their Gini coefficients fell in an intermediate range of roughly 0.2 to 0.4, consistent with partial regulation as cofactors, though the values varied more than threefold across vitamins, likely reflecting differences in diet, absorption, supplementation, and microbiome interactions.

The study’s second focus was ergothioneine, a sulfur-containing amino acid derivative with the formula C9H15N3O2S and an exact monoisotopic mass of 229.0885 Da. Humans cannot synthesise this compound; it comes entirely from the diet, most notably mushrooms, and is transported into tissues by a dedicated transporter. Growing evidence links higher ergothioneine levels to reduced risks of cardiovascular disease, cognitive decline, dementia, and frailty, and previous work by the same group showed that women with high plasma ergothioneine were far less likely to develop pre-eclampsia. Because ergothioneine is exogenous but clearly physiologically important, the team predicted it would show an intermediate Gini coefficient, and the data confirmed this. Across multiple independent studies, ergothioneine’s Gini coefficient clustered consistently between 0.3 and 0.4: 0.38 in the COPD dataset, 0.373 in the tuberculosis cohort, 0.325 in a whole-blood dementia study, 0.457 in an ageing study, and 0.37 to 0.4 in a large dementia cohort from Singapore.

The analytical chemistry behind these measurements is itself noteworthy. Ergothioneine’s protonated form has a mass-to-charge ratio of 230.0958 in positive electrospray ionisation mode, and no other biologically relevant molecule lies within even 10 parts per million of this value, making database searches for the compound unusually straightforward. In new experimental work reported in the paper, the team measured ergothioneine in 40 antenatal serum samples from a pilot study at Liverpool Women’s Hospital, using ultra-high performance liquid chromatography coupled to an Orbitrap Exploris 240 mass spectrometer at a resolution of 120,000, with calibration solutions spanning 0.01 to 500 micromolar.

The Liverpool pilot delivered two surprises. First, the median ergothioneine concentration was just 180 nanograms per millilitre, far below the 261 nanograms per millilitre median seen in the earlier SCOPE study of 432 pregnant women; in fact, 180 nanograms per millilitre corresponds only to the ninth percentile of the earlier cohort. Second, women who went on to develop pre-eclampsia did not show the expected lower ergothioneine levels. The authors suggest this apparent contradiction dissolves once the population’s very low baseline is recognised: when nearly everyone is deficient, the protective relationship with concentration is obscured. Intriguingly, the Gini coefficient in the Liverpool cohort was lower than in almost all other ergothioneine studies, hinting that a depressed Gini value, even without absolute concentrations, might flag a population with inadequate ergothioneine exposure and a likely need for supplementation.

The researchers propose rough interpretive thresholds: metabolites with Gini coefficients below about 0.25 are subject to significant homeostasis or show low variation in exogenous supply, while those above about 0.75 are likely exogenous and largely unregulated. Molecules in between, like most vitamins and the nutraceuticals ergothioneine and kynurenic acid, are probably exogenous but partially regulated. The authors caution that a high Gini coefficient could sometimes reflect analytical error, missing values, or variable pharmacokinetics, making the metric best viewed as hypothesis-generating. A low value, however, is hard to explain away, and reliably indicates tight biological control. The team also notes that urinary metabolomes did not show systematically higher Gini coefficients than plasma, and that applying the approach to gut microbiome-derived metabolites awaits raw data that are not yet publicly available.

Beyond its technical contribution, the work carries a broader message about health inequality. The Liverpool findings, with median ergothioneine levels sitting at the ninth percentile of a comparable cohort, echo documented patterns of socioeconomic disparity in British health and mortality statistics. If a simple statistic borrowed from economics can simultaneously identify which molecules the body defends, expose hidden dietary deficits, and strengthen the case for targeted nutritional intervention, the Gini coefficient may prove to be one of the most versatile imports metabolomics has ever received from the social sciences.

Subject of Research: Using the Gini coefficient as a surrogate measure of metabolite regulability and homeostasis, with a focus on the diet-derived antioxidant ergothioneine

Article Title: The Gini coefficient as a surrogate for the regulability or homeostasis of metabolite concentrations: focus on ergothioneine

Article References: Kell, D. B., Dunn, W. B., Winder, C. L., Anand, K., Greenfield, B., Kenny, L. C., Merriel, A., Moore, J. B., & Waitt, C. (2026). The Gini coefficient as a surrogate for the regulability or homeostasis of metabolite concentrations: focus on ergothioneine. Metabolomics, 22(5), Article 151. https://doi.org/10.1007/s11306-026-02534-1

Image Credits: AI Generated

DOI: 10.1007/s11306-026-02534-1

Keywords: Gini coefficient, metabolomics, ergothioneine, homeostasis, metabolite regulation, nutraceutical, pre-eclampsia, mass spectrometry, amino acids, vitamins, dietary antioxidants, health inequality